Please assess the completion status of the following clinical trial:

Trial Title: Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Documented PAF:~   * Diagnosis of paroxysmal atrial fibrillation (PAF), AND~  * 2 or more episodes of AF during the 3 months preceding the consent Date, AND~  * At least 1 episode of AF documented with a tracing within 12 months preceding the consent date.~2. Age 18 years or older~3. Failure for the treatment of AF (effectiveness or intolerance) of at least one membrane active AAD for rhythm control.~Exclusion Criteria:~1. Any previous left atrial (LA) ablation (except permissible retreatment subjects)~2. Any previous LA surgery~3. Current intracardiac thrombus (can be treated after thrombus is resolved)~4. Presence of any pulmonary vein stents~5. Presence of any pre-existing pulmonary vein stenosis~6. Pre-existing hemidiaphragmatic paralysis~7. Anteroposterior LA diameter \> 5.5 cm by TTE~8. Presence of any cardiac valve prosthesis~9. Clinically significant mitral valve regurgitation or stenosis~10. Myocardial infarction, PCI / PTCA or coronary artery stenting which occurred during the 3 month interval preceding the Consent Date~11. Unstable angina~12. Any cardiac surgery which occurred during the 3 month interval preceding the Consent Date~13. Any significant congenital heart defect corrected or not (including atrial septal defects or pulmonary vein abnormalities but not including minor PFO)~14. NYHA class III or IV congestive heart failure~15. Left ventricular ejection fraction (LVEF) \< 40%~16. 2º (Type II) or 3º atrioventricular block~17. Presence of a permanent pacemaker, biventricular pacemaker, atrial defibrillator or any type of implantable cardiac defibrillator (with or without biventricular pacing function)~18. Brugada syndrome~19. Long QT syndrome~20. Arrhythmogenic right ventricular dysplasia~21. Sarcoidosis~22. Hypertrophic cardiomyopathy~23. Known cryoglobulinemia~24. Uncontrolled hyperthyroidism~25. Any cerebral ischemic event (strokes or TIAs) which occurred during the 6 month interval preceding the Consent Date.~26. Any woman known to be pregnant~27. Life expectancy less than one (1) year~28. Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of this study not pre-approved by Medtronic~29. Unwilling or unable to comply fully with study procedures and followup

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: OTHER): Cryoablation

Based on this trial design, predict the completion outcome and termination type (if applicable).